Source: Cells. Unidades: FMVZ, FZEA
Subjects: CÃES, IMUNOHISTOQUÍMICA, MASTOCITOMA ANIMAL
ABNT
MACEDO, Thais Rodrigues et al. Imatinib mesylate for the treatment of canine mast cell tumors: assessment of the response and adverse events in comparison with the conventional therapy with vinblastine and prednisone. Cells, v. 11, n. 3, p. 1-12, 2022Tradução . . Disponível em: https://doi.org/10.3390/cells11030571. Acesso em: 24 ago. 2024.APA
Macedo, T. R., Queiroz, G. F. de, Casagrande, T. A. C., Alexandre, P. A., Brandão, P. E., Fukumasu, H., et al. (2022). Imatinib mesylate for the treatment of canine mast cell tumors: assessment of the response and adverse events in comparison with the conventional therapy with vinblastine and prednisone. Cells, 11( 3), 1-12. doi:10.3390/cells11030571NLM
Macedo TR, Queiroz GF de, Casagrande TAC, Alexandre PA, Brandão PE, Fukumasu H, Melo SR, Dagli MLZ, Pinto ACB de CF, Matera JM. Imatinib mesylate for the treatment of canine mast cell tumors: assessment of the response and adverse events in comparison with the conventional therapy with vinblastine and prednisone [Internet]. Cells. 2022 ; 11( 3): 1-12.[citado 2024 ago. 24 ] Available from: https://doi.org/10.3390/cells11030571Vancouver
Macedo TR, Queiroz GF de, Casagrande TAC, Alexandre PA, Brandão PE, Fukumasu H, Melo SR, Dagli MLZ, Pinto ACB de CF, Matera JM. Imatinib mesylate for the treatment of canine mast cell tumors: assessment of the response and adverse events in comparison with the conventional therapy with vinblastine and prednisone [Internet]. Cells. 2022 ; 11( 3): 1-12.[citado 2024 ago. 24 ] Available from: https://doi.org/10.3390/cells11030571